Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Air Pollution May Increase the Risk of RA & RA-Associated ILD

Arthritis & Rheumatology  |  June 25, 2025

With the number of wildfires in the U.S. increasing, the corresponding higher levels of particulate matter (PM)—the main pollutant in fire smoke—in the environment may be negatively affecting human health. Prior research has found that PM levels less than 2.5 μm (PM2.5) may be associated with anti-citrullinated protein antibody production, a hallmark of rheumatoid arthritis (RA), as well as the onset of diabetes, Parkinson’s and other conditions. Thus, fire smoke may be a risk factor for RA.

Past research has indicated that other air pollutants, such as carbon monoxide, nitrogen oxides, ozone, PM10 and sulfur dioxide, may also increase the risk of RA, interstitial lung abnormalities and idiopathic pulmonary fibrosis.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a patient-control study, Kronzer et al. sought to better determine the associations between fire smoke and other pollutants with incident RA and RA-associated interstitial lung disease (ILD), as well as identify the timing of the associations.

Methods

Using U.S. Veterans Affairs patient data from Oct. 1, 2009, to Dec. 31, 2018, the researchers identified patients with incident RA and RA-associated ILD using validated algorithms, matching each patient to 10 or fewer controls based on age, sex and VA enrollment year.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Next, researchers obtained nationwide pollutant monitoring data from the U.S. Environmental Protection Agency, including data on fire smoke PM2.5, carbon monoxide, nitrogen oxides, ozone, overall PM2.5, PM10 and sulfur dioxide, at least one year before the index date—defined as the time of RA diagnosis.

The study used conditional logistic regression models to estimate the adjusted odds ratios (aORs) with 95% confidence intervals (CI) for incident RA and RA-associated ILD, adjusted for confounders.

The Results

The study identified 9,701 patients with incident RA (mean age 65 years, 86% male), including 531 patients with RA-associated ILD (mean age 69 years, 91% male) and 68,852 matched controls. The first key finding was that exposure to high levels of PM2.5 from fire smoke was associated with RA-associated ILD (aOR 1.98; 95% CI 1.08–3.62, per 1 μg/m3), but not with overall RA (aOR 1.07; 95% CI 0.92–1.23). However, the stratified analyses showed an association between exposure to high levels of PM2.5 and RA in the one to five years before RA diagnosis.

The study’s second key finding was that high levels of other pollutants, such as nitrogen oxide, were associated with incident RA overall (aOR 1.16; 95% CI 1.06–1.27). Additionally, ozone (aOR 1.19, 95% CI 1.06–1.34) and PM10 (aOR 1.25, 95% CI 1.10–1.43) levels were associated with seronegative RA. The other pollutants studied, including carbon monoxide, overall PM2.5 and sulfur dioxide, were not associated—or even inversely associated—with RA and RA-associated ILD.

For complete details, including source material, refer to the full study.   


Excerpted and adapted from:

Kronzer VL, Yang Y, Roul P, et al. Associations of fire smoke and other pollutants with incident rheumatoid arthritis and rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2025 Jun;77(6).

Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:air pollutionArthritis & Rheumatologyenvironmental factorILDinterstitial lung disease (ILD)Rheumatoid Arthritis (RA)

Related Articles

    What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

    December 1, 2012

    Patients with systemic sclerosis (SSc), poly-/dermatomyositis (PM/DM), or rheumatoid arthritis (RA) appear to carry the greatest risk for developing connective tissue disease-associated interstitial lung disease (CTD-ILD)
     

    Air Pollution: Is There an Association with Rheumatic Disease?

    December 17, 2015

    Interactions between an individual’s genetic background and their exposure to environmental factors are thought to result in a cascade of immune reactions, ultimately leading to the development of autoimmune diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and juvenile dermatomyositis.1,2 For example, an environmental factor that conclusively affects susceptibility…

    Scleroderma & ILD: Practical Tips on the Diagnosis & Management of Systemic Sclerosis-Associated Interstitial Lung Disease

    June 15, 2022

    No one-size-fits-all approach exists for the care and treatment of patients with systemic sclerosis (SSc) and SSc with pulmonary involvement. Here, experts discuss some best clinical practices for these patients.

    Tocilizumab Effective for Early SSc-Associated Interstitial Lung Disease

    September 22, 2021

    Treatment with tocilizimab preserved lung function in patients with systemic sclerosis (SSc) and interstitial lung disease (ILD) regardless of a patient’s level of lung involvement, according to a recent study.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences